What's new

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 64, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 64, Status: Authorised

Mar 17, 2025 - 13:42
 0
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 64, Status: Authorised
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 64, Status: Authorised
Read More

Tags:

Previous Article

Workshop managers share concerns over potential MOT recall rule change

Next Article

Health Canada approves RetinaLogik’s VR visual exam platform

Related Posts

Orphan designation: paltusotine Treatment of acromegaly, 26/02/2025 Positive

Orphan designation: paltusotine Treatment of acromegaly...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Yorvipath, Palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 6, 2025  0

EMEA-003470-PIP01-23

EMEA-003470-PIP01-23

Mar 7, 2025  0